CL2019002521A1 - Método para producir anticuerpos multiespecíficos. - Google Patents
Método para producir anticuerpos multiespecíficos.Info
- Publication number
- CL2019002521A1 CL2019002521A1 CL2019002521A CL2019002521A CL2019002521A1 CL 2019002521 A1 CL2019002521 A1 CL 2019002521A1 CL 2019002521 A CL2019002521 A CL 2019002521A CL 2019002521 A CL2019002521 A CL 2019002521A CL 2019002521 A1 CL2019002521 A1 CL 2019002521A1
- Authority
- CL
- Chile
- Prior art keywords
- cell
- expressed
- antibody
- policy
- multispecific antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
EN LA PRESENTE SE PROPORCIONA UN MÉTODO PARA PRODUCIR UN ANTICUERPO MULTIESPECÍFICO QUE COMPRENDE LAS SIGUIENTES ETAPAS: PROPORCIONAR UNA CÉLULA DE MAMÍFERO QUE EXPRESA EL ANTICUERPO, TRANSFECTAR DICHA CÉLULA DE MAMÍFERO CON UN VECTOR DE EXPRESIÓN QUE COMPRENDE UN CASETE DE EXPRESIÓN QUE CODIFICA UN POLIPÉPTIDO DEL ANTICUERPO QUE TIENE UN ENTRECRUZAMIENTO DE DOMINIOS, CULTIVAR LA CÉLULA TRANSFECTADA Y RECUPERAR EL ANTICU DE LA CÉLULA O DEL MEDIO DE CULTIVO Y PRODUCIR ASÍ EL ANTICUERPO MULTIESPECÍFICO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17160415 | 2017-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019002521A1 true CL2019002521A1 (es) | 2020-01-31 |
Family
ID=58266981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019002521A CL2019002521A1 (es) | 2017-03-10 | 2019-09-02 | Método para producir anticuerpos multiespecíficos. |
Country Status (18)
Country | Link |
---|---|
US (2) | US20200216553A1 (es) |
EP (1) | EP3592767A1 (es) |
JP (2) | JP7021245B2 (es) |
KR (2) | KR20210132207A (es) |
CN (1) | CN110402253B (es) |
AU (1) | AU2018232698B2 (es) |
BR (1) | BR112019016970A2 (es) |
CA (1) | CA3052357A1 (es) |
CL (1) | CL2019002521A1 (es) |
CR (1) | CR20190397A (es) |
IL (1) | IL268470A (es) |
MA (1) | MA48723A (es) |
MX (1) | MX2019010575A (es) |
NZ (1) | NZ756132A (es) |
PE (1) | PE20191360A1 (es) |
RU (1) | RU2750721C2 (es) |
SG (1) | SG11201908127WA (es) |
WO (1) | WO2018162517A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG175077A1 (en) | 2009-04-07 | 2011-11-28 | Roche Glycart Ag | Trivalent, bispecific antibodies |
CN114031689A (zh) * | 2015-10-02 | 2022-02-11 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
EP3947437A1 (en) | 2019-03-29 | 2022-02-09 | F. Hoffmann-La Roche AG | Method for the generation of an fcrn expressing cell by targeted integration of multiple expression cassettes in a defined organization |
EP3966332A4 (en) * | 2019-05-07 | 2023-01-25 | Amgen, Inc. | VECTORS AND EXPRESSION SYSTEMS TO PRODUCE RECOMBINANT PROTEINS |
EP3986928A1 (en) | 2019-06-19 | 2022-04-27 | F. Hoffmann-La Roche AG | Method for the generation of a protein expressing cell by targeted integration using cre mrna |
AU2020294878A1 (en) | 2019-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
BR112021025500A2 (pt) | 2019-06-19 | 2022-02-01 | Hoffmann La Roche | Métodos para produzir um anticorpo multivalente biespecífico e para produzir uma célula de mamífero recombinante, ácido desoxirribonucleico, uso de um ácido desoxirribonucleico, célula de mamífero recombinante e composição |
BR112021025462A2 (pt) | 2019-06-19 | 2022-02-01 | Hoffmann La Roche | Métodos para produzir um anticorpo bivalente biespecífico e uma célula de mamífero recombinante, ácido desoxirribonucleico, uso de um ácido desoxirribonucleico, célula de mamífero recombinante e composição |
KR20220024637A (ko) | 2019-06-19 | 2022-03-03 | 에프. 호프만-라 로슈 아게 | 정의된 조직의 다수 발현 카세트들의 표적화 통합에 의한 3가 항체 발현 세포의 생성 방법 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4912038A (en) | 1984-12-11 | 1990-03-27 | California Biotechnology Inc. | Recombinant DNA sequence encoding alveolar surfactant protein |
DE3688418T2 (de) | 1985-02-13 | 1993-08-26 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
US5550036A (en) | 1986-04-09 | 1996-08-27 | Eli Lilly And Company | Method for co-amplification of human protein C genes in human cells |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
WO1989000605A1 (en) | 1987-07-16 | 1989-01-26 | Codon | Transfected cells containing plasmids having genes oriented in opposing directions and methods of obtaining the same |
CA1341235C (en) | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
EP0319206A3 (en) | 1987-11-30 | 1990-04-18 | Berlex Laboratories, Inc. | Gene amplification |
WO1989010959A1 (en) | 1988-05-06 | 1989-11-16 | Codon | Supertransformants for high expression rates in eukaryotic cells |
DD287531A5 (de) | 1988-06-16 | 1991-02-28 | Akademie Der Wissenschaften,De | Verfahren zur herstellung von humanem wachstumshormon (sth) in tierischen zellen |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
GB9114468D0 (en) | 1991-07-04 | 1991-08-21 | Wellcome Found | Antibody production |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
EP0569678A3 (en) | 1992-03-13 | 1994-10-26 | Yeda Res & Dev | Double transfectants of MHC genes as cellular vaccines for immunoprevention of tumor metastasis. |
US6482919B2 (en) * | 1993-02-01 | 2002-11-19 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5420019A (en) | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
DK0802800T3 (da) | 1993-08-12 | 2002-10-07 | Neurotech Sa | Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler |
WO1995017513A1 (en) | 1993-12-23 | 1995-06-29 | Novo Nordisk A/S | Retransformation of filamentous fungi |
US5719050A (en) | 1993-12-24 | 1998-02-17 | Eiken Chemical Co., Ltd. | Animal cell culturing media containing N-acetyl-L-glutamic acid |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
WO1997008342A1 (en) | 1995-08-30 | 1997-03-06 | Gentest Corporation | Cytochrome p450 reporter gene |
EP0953041A4 (en) | 1996-08-30 | 2003-01-29 | Life Technologies Inc | SERUM-FREE CULTURAL MEDIUM FOR MAMMAL CELLS AND THEIR USE |
JP4436934B2 (ja) | 1996-09-13 | 2010-03-24 | ノボザイムス,インコーポレイティド | 変更された量のポリペプチドを生成するdna挿入突然変異を有する細胞 |
IL132560A0 (en) | 1997-05-02 | 2001-03-19 | Genentech Inc | A method for making multispecific antibodies having heteromultimeric and common components |
US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
JP2002503444A (ja) | 1997-11-26 | 2002-02-05 | イーライ・リリー・アンド・カンパニー | リガンドファミリー遺伝子 |
AU2767999A (en) | 1998-03-18 | 1999-10-11 | Pharmacopeia, Inc. | Eukaryotic cells stably expressing genes from multiple transfected episomes |
BR9905867A (pt) | 1998-11-06 | 2001-01-23 | Bio Sidus S A | Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula |
TW570977B (en) | 1998-12-07 | 2004-01-11 | Li-Wei Hsu | An expression system for producing recombinant human erythropoietin, method for purifying secreted human erythropoietin and uses thereof |
DE19920712A1 (de) | 1999-05-05 | 2000-11-09 | Rhein Biotech Proz & Prod Gmbh | Verfahren zum Herstellen eines rekombinanten Proteines |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
AUPQ422399A0 (en) | 1999-11-24 | 1999-12-16 | University Of New South Wales, The | Method of screening transformed or transfected cells |
PL357939A1 (en) | 2000-04-11 | 2004-08-09 | Genentech, Inc. | Multivalent antibodies and uses therefor |
JP2002027581A (ja) | 2000-07-13 | 2002-01-25 | Npl:Kk | スピーカ |
DE10036491A1 (de) | 2000-07-25 | 2002-02-07 | Roche Diagnostics Gmbh | Expression von Alkalischer Phosphatase in Hefe |
EP1383800A4 (en) | 2001-04-02 | 2004-09-22 | Idec Pharma Corp | RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII |
US20030157641A1 (en) * | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
MXPA04005191A (es) | 2001-11-28 | 2005-04-29 | Sandoz Ag | Metodo para producir un polipeptido recombinante. |
EP1488234A4 (en) | 2002-03-05 | 2006-05-24 | Vitra Bioscience Inc | TRANSFECTION OF MULTIPLEXED CELLS USING CODED MEDIA |
DE10213201A1 (de) | 2002-03-25 | 2003-10-16 | Roche Diagnostics Gmbh | Erzeugung von schwach aktiven oder inaktiven Mutanten von Alkalischer Phosphatase und deren Expression in Hefe |
US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
WO2005113770A1 (en) | 2004-05-13 | 2005-12-01 | Institut Gustave Roussy | Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them. |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
DE102005046225B4 (de) | 2005-09-28 | 2012-01-05 | Cellca Gmbh | Verbessertes Zellkulturmedium |
PL1999154T3 (pl) | 2006-03-24 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe |
EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
EP3112382A1 (en) | 2009-12-29 | 2017-01-04 | Emergent Product Development Seattle, LLC | Heterodimer binding proteins and uses thereof |
CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
JP5997154B2 (ja) | 2010-08-16 | 2016-09-28 | ノビミューン エスアー | 多重特異性多価抗体の生成方法 |
CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
US10150968B2 (en) * | 2011-08-19 | 2018-12-11 | Alderbio Holdings Llc | Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
BR112014003769B1 (pt) | 2011-08-23 | 2022-05-10 | Roche Glycart Ag | Molécula de ligação ao antígeno biespecífica ativadora de célula t, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t |
LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
PT2838917T (pt) | 2012-04-20 | 2019-09-12 | Merus Nv | Métodos e meios para a produção de moléculas similares a ig heterodiméricas |
RU2646159C2 (ru) * | 2012-09-14 | 2018-03-01 | Ф. Хоффманн-Ля Рош Аг | Способ получения и отбора молекул, включающих по меньшей мере две различные группировки, и их применение |
MA38308B1 (fr) | 2013-02-26 | 2022-09-30 | Hoffmann La Roche | Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t |
US20160009824A1 (en) | 2013-03-15 | 2016-01-14 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
BR112016006929A2 (pt) * | 2013-10-11 | 2017-09-19 | Hoffmann La Roche | Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo |
BR112016015589A2 (pt) | 2014-01-06 | 2017-10-31 | Hoffmann La Roche | módulos de trânsito monovalentes para a barreira hematoencefálica |
JP6744292B2 (ja) | 2014-07-29 | 2020-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性抗体 |
CN106999580B (zh) | 2014-10-08 | 2021-07-06 | 豪夫迈·罗氏有限公司 | 对fap和dr5特异性的双特异性抗体和化疗剂的组合疗法 |
EP3356411B1 (en) | 2015-10-02 | 2021-06-30 | F. Hoffmann-La Roche AG | Bispecific antibodies specific for pd1 and tim3 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
CN114031689A (zh) | 2015-10-02 | 2022-02-11 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
-
2018
- 2018-03-07 AU AU2018232698A patent/AU2018232698B2/en not_active Ceased
- 2018-03-07 CR CR20190397A patent/CR20190397A/es unknown
- 2018-03-07 MX MX2019010575A patent/MX2019010575A/es unknown
- 2018-03-07 CN CN201880017305.XA patent/CN110402253B/zh active Active
- 2018-03-07 MA MA048723A patent/MA48723A/fr unknown
- 2018-03-07 KR KR1020217033969A patent/KR20210132207A/ko not_active Application Discontinuation
- 2018-03-07 BR BR112019016970A patent/BR112019016970A2/pt not_active IP Right Cessation
- 2018-03-07 KR KR1020197028604A patent/KR20190124270A/ko not_active Application Discontinuation
- 2018-03-07 EP EP18710013.6A patent/EP3592767A1/en active Pending
- 2018-03-07 JP JP2019548911A patent/JP7021245B2/ja active Active
- 2018-03-07 RU RU2019131113A patent/RU2750721C2/ru active
- 2018-03-07 PE PE2019001714A patent/PE20191360A1/es unknown
- 2018-03-07 CA CA3052357A patent/CA3052357A1/en not_active Abandoned
- 2018-03-07 NZ NZ756132A patent/NZ756132A/en not_active IP Right Cessation
- 2018-03-07 SG SG11201908127W patent/SG11201908127WA/en unknown
- 2018-03-07 WO PCT/EP2018/055532 patent/WO2018162517A1/en active Application Filing
-
2019
- 2019-08-04 IL IL268470A patent/IL268470A/en unknown
- 2019-09-02 CL CL2019002521A patent/CL2019002521A1/es unknown
- 2019-09-04 US US16/560,375 patent/US20200216553A1/en not_active Abandoned
-
2021
- 2021-09-29 JP JP2021158599A patent/JP2022001059A/ja active Pending
-
2022
- 2022-05-25 US US17/804,072 patent/US20230129340A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018162517A1 (en) | 2018-09-13 |
US20230129340A1 (en) | 2023-04-27 |
AU2018232698A1 (en) | 2019-08-15 |
NZ756132A (en) | 2022-02-25 |
KR20210132207A (ko) | 2021-11-03 |
CA3052357A1 (en) | 2018-09-13 |
US20200216553A1 (en) | 2020-07-09 |
EP3592767A1 (en) | 2020-01-15 |
CN110402253A (zh) | 2019-11-01 |
MA48723A (fr) | 2020-04-08 |
BR112019016970A2 (pt) | 2020-04-07 |
IL268470A (en) | 2019-09-26 |
JP2022001059A (ja) | 2022-01-06 |
RU2750721C2 (ru) | 2021-07-01 |
KR20190124270A (ko) | 2019-11-04 |
PE20191360A1 (es) | 2019-10-01 |
MX2019010575A (es) | 2019-10-15 |
JP7021245B2 (ja) | 2022-02-16 |
AU2018232698B2 (en) | 2020-06-25 |
SG11201908127WA (en) | 2019-10-30 |
RU2019131113A3 (es) | 2021-04-12 |
JP2020509754A (ja) | 2020-04-02 |
CN110402253B (zh) | 2024-01-05 |
RU2019131113A (ru) | 2021-04-12 |
CR20190397A (es) | 2019-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019002521A1 (es) | Método para producir anticuerpos multiespecíficos. | |
CO2019009365A2 (es) | Anticuerpos anti-lag3 | |
CU20190100A7 (es) | Anticuerpos biespecíficos y método de fabricación de los mismos | |
CL2020003409A1 (es) | Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154) | |
AR120262A2 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso | |
CO2018000710A2 (es) | Anticuerpos biespecíficos específicos para un receptor de tnf coestimulador | |
CR20220186A (es) | ANTICUERPOS ANTI-TIGIT Y MÉTODOS DE USO (divisional 2018-0225) | |
CU24533B1 (es) | Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos | |
CL2017000545A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
CR20190309A (es) | Moleculas de unión de3 antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb | |
MY198059A (en) | Anti-ox40 antibodies and their uses | |
BR112018074468A2 (pt) | anticorpos anti-cd40 e suas utilizações | |
TR2021016542A2 (tr) | Plazma bazlı filmler ve bunları üretme ve kullanma usulleri. | |
PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
PE20170289A1 (es) | Anticuerpos anti tigit | |
AR096839A1 (es) | Proceso mejorado para la producción de anticuerpos monoclonales | |
MX2022000893A (es) | Metodo de obtencion de mitocondrias de celulas y mitocondrias obtenidas. | |
AR095348A1 (es) | Medios de cultivo celular y métodos de producción de anticuerpos | |
CL2019002894A1 (es) | Anticuerpo monoclonal para pd-l1. | |
AR099552A1 (es) | Sistema y método para facilitar préstamos financieros | |
NI202000087A (es) | Anticuerpos ant-tmeff2 monoespecíficos y multiespecíficos y sus usos | |
DOP2016000220A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS. | |
EA202090766A1 (ru) | Крупномасштабное производство жидких и твердых продуктов на основе trichoderma | |
PL439808A1 (pl) | Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał | |
ECSP20024551A (es) | ANTICUERPO MONOCLONAL PARA IL-5Ra |